Search Within

Shanu Modi

  1. "2018"
Formats
  1. Meeting Abstract (12)
  2. Journal Article (5)
Groups
  1. Breast Medicine Service (17)
  2. Department of Medicine (17)
  3. Solid Tumor Oncology Division (17)
  4. GSK Faculty (7)
  5. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (5)
  6. Epidemiology and Biostatistics (5)

More Groups

People
  1. Bob Li (4)
  2. Sarat Chandarlapaty (4)
  3. Chau Dang (3)
  4. Clifford Hudis (3)
  5. Jose Baselga (3)
  6. Larry Norton (3)

More People

Years
  1. 2018 (17)
Publications
  1. Journal of Clinical Oncology (7)
  2. Cancer Research (3)
  3. Annals of Oncology (2)
  4. Cancer Cell (1)
  5. Clinical Breast Cancer (1)
  6. JAMA Dermatology (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (7)
  2. American Association for Cancer Research (3)
  3. Elsevier Inc. (2)
  4. Oxford University Press (2)
  5. American Medical Association (1)
  6. Cell Press (1)

More Publishers

Results (17)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Longer follow-up on clinical outcomes of weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2 overexpressing metastatic breast cancer
    Meeting Abstract

    Wang, R.; Smyth, L. M.; Iyengar, N. M.; Modi, S.; Chandarlapaty, S.; Patil, S.; Norton, L.; Baselga, J.; Hudis, C. A.; Dang, C. T.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing solid tumors: Long-term results of a large phase 1 study with multiple expansion cohorts
    Meeting Abstract

    Iwata, H.; Tamura, K.; Doi, T.; Tsurutani, J.; Modi, S.; Park, H.; Krop, I. E.; Sagara, Y.; Redfern, C. H.; Murthy, R. K.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • A phase 2, multicenter, open-label study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-positive, unresectable and/or metastatic breast cancer previously treated with T-DM1
    Meeting Abstract

    Baselga, J.; Tamura, K.; Yamashita, T.; Modi, S.; Tokunaga, E.; Ito, Y.; Iwata, H.; Charif, M.; Lee, C. C.; Sugihara, M.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Baseline gene expression patterns of CDK4/6 inhibitor-naïve or -refractory HR+, HER2-advanced breast cancer in the phase Ib study of ribociclib plus everolimus plus exemestane
    Meeting Abstract

    Bardia, A.; Modi, S.; Cortes, J.; Campone, M.; Dirix, L.; Ma, B.; Beck, J. T.; Chaves, J.; Weise, A.; Vuky, J.; more...
    Cancer Research (2018)

    Fulltext@MSK | Save
  • Updated results of phase I study of trastuzumab deruxtecan (DS-8201a) in HER2-expressing advanced colorectal cancer
    Meeting Abstract

    Yoshino, T.; Iwata, H.; Tamura, K.; Takahashi, S.; Redfern, C.; Modi, S.; Doi, T.; Kawakami, H.; Taniguchi, H.; Takashima, A.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Post-treatment biopsies show evidence of cell cycle arrest and immune cell infiltration into tumors of ladiratuzumab vedotin-treated advanced breast cancer patients
    Meeting Abstract

    Specht, J.; Pusztai, L.; Forero-Torres, A.; Mita, M.; Weise, A.; Krop, I.; Grosse-Wilde, A.; Wang, Z.; Li, M.; Hengel, S.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Updated results of phase 1 study of DS-8201a in HER2-expressing or -mutated advanced non-small-cell lung cancer
    Meeting Abstract

    Tsurutani, J.; Park, H.; Doi, T.; Modi, S.; Takahashi, S.; Nakagawa, K.; Krop, I.; Waqar, S.; Yoh, K.; Li, B.; more...
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • Safety and tolerability of adjuvant enzalutamide for the treatment of early stage androgen receptor positive (AR+) triple negative breast cancer
    Meeting Abstract

    Lyons, T.; Gucalp, A.; Arumov, A.; Patil, S.; Edelweiss, M.; Gorsky, M.; Troso-Sandoval, T. A.; Bromberg, J.; Sanford, R. A.; Iyengar, N. M.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Updated results of phase 1 study of DS-8201a in subjects with HER2-expressing gastric cancer
    Meeting Abstract

    Iwasa, S.; Shitara, K.; Takahashi, S.; Park, H.; Kadowaki, S.; Modi, S.; Nonagase, Y.; Tamura, K.; Yamaguchi, K.; Muro, K.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: ASCO Clinical Practice Guideline update
    Journal Article

    Ramakrishna, N.; Temin, S.; Chandarlapaty, S.; Crews, J. R.; Davidson, N. E.; Esteva, F. J.; Giordano, S. H.; Kirshner, J. J.; Krop, I. E.; Levinson, J.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save